周教授：目前已有足够数据支持围手术期免疫治疗（新辅助化疗联合免疫治疗+辅助免疫治疗）在早期可切除NSCLC患者中的应用。综合多项试验数据，III期或II期患者可能从围手术免疫治疗中获益更多，病理完全缓解（pCR）率约为25%，这一数值在新辅助化疗中并不常见。我认为III期或II期NSCLC患者更应接受围手术期治疗，该疗法的安全性尚可接受，大部分患者的不良事件为1级或2级，且可通过常规手段管理。

 

Dr.Zhou:Nowadays，we have enough data to support neoadjuvant chemo-IO and adjuvant IO in early stage resectable non-small cell lung cancer.When we look at all the data across trials，maybe stage 3 or stage 2 can get much more benefit from this therapy.The pCR rate is around 25%，which is not bad and seldom seen with neoadjuvant chemotherapy.I do think stage 3 or stage 2 get more benefit from perioperative neoadjuvant chemo-IO therapy.The safety profile of this therapy is acceptable.The majority of patients experience grade 1 or grade 2 adverse events.The majority of events are manageable with common practices.I support neoadjuvant plus adjuvant chemo-IO in the early stage NSCLC.